CRI presented the award to Dr. Rao during a special reception and dinner for CRI-funded graduate students and postdoctoral fellows held the evening of September 30 at The Harvard Club in New York City. The dinner took place in conjunction with the Institute’s 17th Annual International Cancer Immunotherapy Symposium, held Sept. 30-Oct. 2, 2009.
In her presentation of the award to Dr. Rao, Dr. Ellen Puré, professor of the Molecular and Cellular Oncogenesis Program at The Wistar Institute in Philadelphia, PA, and chair of the Cancer Research Institute Postdoctoral Fellowship Committee, lauded Dr. Rao’s seminal contributions to our understanding of the role of gene transcription factors in cellular differentiation and function, particularly in immune cells.
Dr. Rao’s research is focused on the molecular mechanisms of signal transduction and gene expression in T lymphocytes, important cells of the immune system that have proven critical to immune control of cancer. Dr. Rao’s early work identified the role of transcription factors in directing T-cell differentiation, especially different functional subsets of T cells.
She elucidated intracellular signal transduction pathways leading from store-operated calcium entry through what is known as CRAC (calcium-release activated calcium entry) channels to activation of the transcription factor known as NFAT (nuclear factor of activated T cells). She also identified the first member of the NFAT family as well as the CRAC channel pore subunit critical to this response.
Her work has defined how NFAT and other transcription factors regulate immune responses including the induction of peripheral immune tolerance and regulatory T-cell function, both of which directly affect the immune system’s ability to eliminate cancer by inhibiting the activity of other immune cells.
Her studies of the genetic and epigenetic regulation of T-cell differentiation have provided critical insights into DNA regulatory regions that are involved in this type of transcriptional regulation, and also in the nuclear processes that control chromatin assembly and expression of genes that direct lineage specification. In addition to having impact on the immune response, her work has broader implications for cell lineage differentiation and specification in general.
Dr. Rao completed her undergraduate and graduate studies in science at Osmania University in Hyderabad, India. In 1978, she received her Ph.D. in biophysics from Harvard University. In 1981, Dr. Rao received a Cancer Research Institute Postdoctoral Fellowship Award while she carried out her postdoctoral training in the lab of Dr. Harvey Cantor at the Dana Farber Cancer Institute. She joined the Harvard faculty in 1981 as an instructor in pathology, became an assistant professor in 1984, an associate professor in 1993, and in 1995 she was appointed as a senior investigator of what was then known as the Center for Blood Research, now known as the Immune Disease Institute, which is headed by Dr. Fred Alt, in whose honor this award is named.
In accepting the award, Dr. Rao expressed her gratitude for the Cancer Research Institute’s support of her work. “The CRI postdoctoral fellowship jumpstarted my career, as it has jumpstarted the careers of so many postdoctoral fellows and students,” she told the audience of current CRI fellows, graduate students, and other members of the CRI community including trustees, scientific advisors, and staff. “Getting such an award at the beginning of your career makes one feel independent—the idea is now that you can do whatever it is you want to do, to think of good ideas and do them.”
The Cancer Research Institute annually bestows thirty fellowship awards totaling approximately $4.4 million. Since the establishment of the CRI Postdoctoral Fellowship Program in 1971 (now called the Irvington Institute Fellowship Program of the Cancer Research Institute), CRI has supported 968 young research scientists, many of whom have since gone on to become leaders in the fields of immunology and tumor immunology.
About the Frederick W. Alt Award for New Discoveries in Immunology
The Frederick W. Alt Award for New Discoveries in Immunology is presented annually to a former postdoctoral fellow of the Cancer Research Institute in recognition of outstanding success in academia or industry for research that may have a potentially major impact on immunology. The award is named after Dr. Frederick W. Alt, co-chief of molecular medicine and the Charles A. Janeway Professor of Pediatrics at the Children’s Hospital in Boston, MA, and a Howard Hughes Medical Institute investigator and professor of genetics at the Harvard Medical School / Immune Disease Institute in Boston, MA, is a member of the Cancer Research Institute Scientific Advisory Council who also served for many years as chair of the Postdoctoral Fellowship Committee of the Irvington Institute for Immunological Research, an organization that merged with the Cancer Research Institute in 2007. For more than 30 years, Dr. Alt has studied how instability within the genome leads to cancer and has worked to uncover the cellular mechanisms that normally suppress this process. His discoveries have led to a greater understanding of the ways that cancer develops, and they hold promise for finding ways to control the disease.
About the Cancer Research Institute
The Cancer Research Institute (CRI) is the world’s only non-profit organization dedicated exclusively to the support and coordination of scientific and clinical efforts that will lead to the immunological treatment, control, and prevention of cancer. Guided by a world-renowned Scientific Advisory Council that includes four Nobel Prize winners and twenty-nine members of the National Academy of Sciences, CRI supports leading-edge cancer research at top medical centers and universities throughout the world. CRI is an initiator and steward of global collaborative research efforts aimed at accelerating the translation of basic discovery into effective cancer vaccines and other immune-based therapies to provide new hope to cancer patients.
The Cancer Research Institute has one of the lowest overhead expense ratios among non-profit organizations, with more than 85 percent of its resources going directly to the support of its science, medical, and research programs. CRI meets or exceeds all 20 standards of the Better Business Bureau Wise Giving Alliance, the most comprehensive U.S. charity evaluation service, and according to Charity Navigator exceeds or meets industry standards and performs as well as or better than most cancer charities. CRI has also received an 'A' grade for fiscal disclosure and efficiency from the American Institute of Philanthropy as well as top accolades from other charity watchdog organizations.
Brian Brewer | Newswise Science News
Further reports about: > Advisory > CRAC > CRI > Cancer > Committee for Advanced Therapies > Disease > Immune cell activation > Immunology > Medical Wellness > Merit Award > NFAT > T cells > T lymphocyte > T-cell > Universität Harvard > cellular mechanism > immune cell > immune response > immune system > molecular mechanism > signal transduction > transcription factor
Muscle Growth in the Computer: International Team Wants to Unravel the Formation of Myofibrils
13.06.2018 | Technische Universität Dresden
Innovation Award of the United Nations Environment Programme for PhD Student from ZMT
22.03.2018 | Leibniz-Zentrum für Marine Tropenforschung (ZMT)
In a recent publication in the renowned journal Optica, scientists of Leibniz-Institute of Photonic Technology (Leibniz IPHT) in Jena showed that they can accurately control the optical properties of liquid-core fiber lasers and therefore their spectral band width by temperature and pressure tuning.
Already last year, the researchers provided experimental proof of a new dynamic of hybrid solitons– temporally and spectrally stationary light waves resulting...
Scientists from the University of Freiburg and the University of Basel identified a master regulator for bone regeneration. Prasad Shastri, Professor of...
Moving into its fourth decade, AchemAsia is setting out for new horizons: The International Expo and Innovation Forum for Sustainable Chemical Production will take place from 21-23 May 2019 in Shanghai, China. With an updated event profile, the eleventh edition focusses on topics that are especially relevant for the Chinese process industry, putting a strong emphasis on sustainability and innovation.
Founded in 1989 as a spin-off of ACHEMA to cater to the needs of China’s then developing industry, AchemAsia has since grown into a platform where the latest...
The BMBF-funded OWICELLS project was successfully completed with a final presentation at the BMW plant in Munich. The presentation demonstrated a Li-Fi communication with a mobile robot, while the robot carried out usual production processes (welding, moving and testing parts) in a 5x5m² production cell. The robust, optical wireless transmission is based on spatial diversity; in other words, data is sent and received simultaneously by several LEDs and several photodiodes. The system can transmit data at more than 100 Mbit/s and five milliseconds latency.
Modern production technologies in the automobile industry must become more flexible in order to fulfil individual customer requirements.
An international team of scientists has discovered a new way to transfer image information through multimodal fibers with almost no distortion - even if the fiber is bent. The results of the study, to which scientist from the Leibniz-Institute of Photonic Technology Jena (Leibniz IPHT) contributed, were published on 6thJune in the highly-cited journal Physical Review Letters.
Endoscopes allow doctors to see into a patient’s body like through a keyhole. Typically, the images are transmitted via a bundle of several hundreds of optical...
13.06.2018 | Event News
08.06.2018 | Event News
05.06.2018 | Event News
22.06.2018 | Materials Sciences
22.06.2018 | Earth Sciences
22.06.2018 | Life Sciences